194 related articles for article (PubMed ID: 34285062)
1.
Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
[TBL] [Abstract][Full Text] [Related]
2. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Malcikova J; Pavlova S; Kunt Vonkova B; Radova L; Plevova K; Kotaskova J; Pal K; Dvorackova B; Zenatova M; Hynst J; Ondrouskova E; Panovska A; Brychtova Y; Zavacka K; Tichy B; Tom N; Mayer J; Doubek M; Pospisilova S
Blood; 2021 Dec; 138(25):2670-2685. PubMed ID: 33945616
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
Blakemore SJ; Clifford R; Parker H; Antoniou P; Stec-Dziedzic E; Larrayoz M; Davis Z; Kadalyayil L; Colins A; Robbe P; Vavoulis D; Forster J; Carr L; Morilla R; Else M; Bryant D; McCarthy H; Walewska RJ; Steele AJ; Chan J; Speight G; Stankovic T; Cragg MS; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Schuh A; Strefford JC
Leukemia; 2020 Jul; 34(7):1760-1774. PubMed ID: 32015491
[TBL] [Abstract][Full Text] [Related]
4. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
5. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
6. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
9. Impact of Low-Burden
Lazarian G; Cymbalista F; Baran-Marszak F
Front Oncol; 2022; 12():841630. PubMed ID: 35211418
[TBL] [Abstract][Full Text] [Related]
10. Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
László T; Kotmayer L; Fésüs V; Hegyi L; Gróf S; Nagy Á; Kajtár B; Balogh A; Weisinger J; Masszi T; Nagy Z; Farkas P; Demeter J; Istenes I; Szász R; Gergely L; Sulák A; Borbényi Z; Lévai D; Schneider T; Pettendi P; Bodai E; Szerafin L; Rejtő L; Bátai Á; Dömötör MÁ; Sánta H; Plander M; Szendrei T; Hamed A; Lázár Z; Pauker Z; Radványi G; Kiss A; Körösmezey G; Jakucs J; Dombi PJ; Simon Z; Klucsik Z; Gurzó M; Tiboly M; Vidra T; Ilonczai P; Bors A; Andrikovics H; Egyed M; Székely T; Masszi A; Alpár D; Matolcsy A; Bödör C
J Pathol Clin Res; 2024 Jan; 10(1):e351. PubMed ID: 37987115
[TBL] [Abstract][Full Text] [Related]
11. The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
De Luca G; Cerruti G; Lastraioli S; Conte R; Ibatici A; Di Felice N; Morabito F; Monti P; Fronza G; Matis S; Colombo M; Fabris S; Ciarrocchi A; Neri A; Menichini P; Ferrarini M; Nozza P; Fais F; Cutrona G; Dono M
Hematol Oncol; 2022 Dec; 40(5):962-975. PubMed ID: 35961859
[TBL] [Abstract][Full Text] [Related]
12. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.
Dong HJ; Fang C; Wang L; Fan L; Xu J; Wu JZ; Lu TX; Li JY; Xu W
Med Oncol; 2014 Apr; 31(4):908. PubMed ID: 24615009
[TBL] [Abstract][Full Text] [Related]
13. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
Short NJ; Montalban-Bravo G; Hwang H; Ning J; Franquiz MJ; Kanagal-Shamanna R; Patel KP; DiNardo CD; Ravandi F; Garcia-Manero G; Takahashi K; Konopleva M; Daver N; Issa GC; Andreeff M; Kantarjian H; Kadia TM
Blood Adv; 2020 Nov; 4(22):5681-5689. PubMed ID: 33211826
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
[TBL] [Abstract][Full Text] [Related]
18. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes in Patients with Multi-Hit
Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
[TBL] [Abstract][Full Text] [Related]
20. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
